Administration of neutralizing antibodies for PN, or WNT3A, or IL17A, or CD44v6 increased the efficacy of FOLFOX-chemotherapy on reducing tumor growth (Figures 8B–E). The gene discussed is IL17A; the disease is neoplasm.